NeuBase Therapeutics
From EverybodyWiki Bios & Wiki
NeuBase Therapeutics is a private biotechnology company based in Pittsburgh, Pennsylvania. It was founded in 2018 by Dietrich Stephan.[1][2][3]
NeuBase is developing its peptide nucleic acid antisense oligonucleotide (PATrOLTM) platform to address rare genetic diseases caused by mutant proteins.[4] The gene silencing platform is initially being used to address the trinucleotide repeat disorders, Huntington's disease and myotonic dystrophy.[1][3][4]
References[edit]
- ↑ 1.0 1.1 Grover, Natalie. "Gene silencing company NeuBase Therapeutics to reverse merge its way onto Nasdaq via troubled microcap Ohr". Endpoints News.
- ↑ Asif, Muhammad Hammad. "Ohr Pharma, NeuBase merger to form genetic disease-focused drug developer". S&P Global.
- ↑ 3.0 3.1 Terry, Mark. "Ohr Pharma and NeuBase Merge to Push NeuBase's Rare Disease Tech Platform". BioSpace.com.
- ↑ 4.0 4.1 Fikes, Bradley. "Biotech kicks off the year with conferences in San Francisco". San Diego Union Tribune.
This article "NeuBase Therapeutics" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:NeuBase Therapeutics. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
